Free tool
FDA Approval Tracker
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
1,560
2012 to 2026
Breakthrough
316
Accelerated
131
Priority review
1560
Orphan
759
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2012 | 42 | 6 |
| 2013 | 39 | 8 |
| 2014 | 54 | 17 |
| 2015 | 58 | 18 |
| 2016 | 55 | 20 |
| 2017 | 86 | 33 |
| 2018 | 99 | 48 |
| 2019 | 100 | 32 |
| 2020 | 86 | 53 |
| 2021 | 86 | 53 |
| 2022 | 84 | 33 |
| 2023 | 77 | 34 |
| 2024 | 82 | 32 |
| 2025 | 72 | 47 |
| 2026 | 59 | 47 |
1,560 approvals
Newest first. Hover a badge for what it means.
- Gazyva (Obinutuzumab) · GenentechNov 13, 2026Efficacy supplement 44 · BLA 125486Priority review
- Imfinzi (Durvalumab) · Astrazeneca Uk LTDNov 13, 2026Efficacy supplement 59 · BLA 761069Priority review
- Zurzuvae (Zuranolone) · BiogenNov 13, 2026Efficacy supplement 4 · NDA 217369Priority review
- Sunharbo (Asundexian) · Bayer HealthcareNov 9, 2026
To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack
- Rybrevant Faspro (Amivantamab and Hyaluronidase-Lpuj) · Janssen BiotechNov 5, 2026
- Talzenna (Talazoparib Tosylate) · PfizerOct 26, 2026
- Talzenna (Talazoparib Tosylate) · PfizerOct 26, 2026
- Skyrizi (Risankizumab-Rzaa) · Abbvie INCOct 23, 2026
- Awiqli Flextouch (Insulin Icodec) · Novo Nordisk INCOct 23, 2026
- Ultomiris (Ravulizumab-Cwvz) · Alexion PharmOct 21, 2026
- Hibsago (Bepirovirsen Sodium) · GlaxosmithklineOct 20, 2026
To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy
- Jemperli (Dostarlimab-Gxly) · GlaxosmithklineOct 19, 2026
- Enspryng (Satralizumab) · GenentechOct 15, 2026
- Hovilpri (Pritelivir Mesylate) · Aicuris Anti-InfectOct 9, 2026
To treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies
- Tecentriq (Atezolizumab) · Genentech INCOct 8, 2026
- Tecentriq Hybreza (Atezolizumab and Hyaluronidase-Tqjs) · Genentech INCOct 8, 2026
- Camzyos (Mavacamten) · BristolSep 30, 2026
- Emcitate (Tiratricol) · Rare ThyroidSep 28, 2026
To treat peripheral thyrotoxicosis in patients with MCT8 deficiency
- Atebrioz (Zilurgisertib Fumarate) · MirumSep 25, 2026
To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva
- Gazyva (Obinutuzumab) · GenentechSep 25, 2026
- Lyrfigtu (Lirafugratinib Hydrochloride) · ElevarSep 23, 2026
To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement
- Aqneursa (Levacetylleucine) · IntrabioSep 18, 2026
- Kerendia (Finerenone) · Bayer HlthcareSep 16, 2026
- Isembyld (Apitegromab-Mstn) · Scholar Rock INCSep 11, 2026
To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment
- Joenja (Leniolisib Phosphate) · PharmingSep 11, 2026
- Pixclara (Floretyrosine F-18) · TelixSep 11, 2026
To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations
- Hyrnuo (Sevabertinib) · Bayer HealthcareSep 9, 2026
- Zanvastro (Zilganersen Sodium) · Ionis Pharms INCSep 3, 2026
To treat Alexander disease in pediatric and adult patients
- Mimrylo (Rusfertide Acetate) · Takeda Pharms AmAug 28, 2026
To treat erythrocytosis in adults with polycythemia vera
- Bixlenvo (Bictegravir Sodium, Lenacapavir Sodium) · Gilead Sciences INCAug 27, 2026
- Lisraya (Brepocitinib Tosylate) · Priovant TherapAug 27, 2026
To treat dermatomyositis in adults
- Rasonque (Daraxonrasib) · Revolution MedicinesAug 26, 2026
To treat metastatic pancreatic cancer
- Tevimbra (Tislelizumab-Jsgr) · BeigeneAug 25, 2026
- Ziihera (Zanidatamab-Hrii) · Jazz PharmsAug 25, 2026
- Tivicay (Dolutegravir Sodium) · Viiv HlthcareAug 25, 2026
- Tivicay Pd (Dolutegravir Sodium) · Viiv HlthcareAug 25, 2026
- Imaavy (Nipocalimab-Aahu) · Janssen BiotechAug 24, 2026
- Pasatru (Garetosmab-Grts) · Regeneron Pharmaceuticals, INCAug 19, 2026
To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva
- Zenbexus (Iberdomide Hydrochloride) · Bristol Myers SquibbAug 13, 2026
To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent
- Orzeyful (Oveporexton) · Takeda Pharms USAAug 5, 2026
To treat narcolepsy type 1
- Simtriyo (Centanafadine Hydrochloride) · OtsukaJul 24, 2026
To treat attention-deficit hyperactivity disorder
- Macrilen (Macimorelin Acetate) · Aeterna ZentarisJul 23, 2026
- Fabhalta (Iptacopan Hydrochloride) · NovartisJul 16, 2026
- Lipfendra (Enlicitide Decanoate) · MsdJul 15, 2026
To reduce low-density lipoprotein cholesterol
- Revtorpyk (Gedatolisib) · CelcuityJul 14, 2026
In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting
- Leqembi Iqlik (Lecanemab-Irmb) · Eisai INCJul 13, 2026
- Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp DohmeJul 10, 2026
- Padcev (Enfortumab Vedotin-Ejfv) · AstellasJul 10, 2026
- Keytruda (Pembrolizumab) · Merck Sharp DohmeJul 10, 2026
- Trutakna (Atacicept-Vymj) · Vera Therapeutics Inc.Jul 7, 2026
To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.